Mark Cushman

Last updated

Mark S. Cushman is an American chemist, whose primary research is in the area of medicinal chemistry. He completed his pre-pharmacy studies at Fresno State College (now California State University, Fresno) in 1965. He then attended the University of California San Francisco (as a University of California Regents Scholar), earning a Pharm.D. in 1969 and a Ph.D. in Medicinal Chemistry in 1973. Thereafter, he performed postdoctoral training in the laboratory of George Büchi, Ph.D., at the Massachusetts Institute of Technology (MIT). There, his research focused on the discovery and development of new synthetic methodologies, [1] and the isolation and structural characterization of mycotoxins from Aspergillus niger. [2] In 1975, he joined the Department of Medicinal Chemistry and Molecular Pharmacology (at the time, Department of Medicinal Chemistry and Pharmacognosy) at Purdue University. From 1983 to 1984, Prof. Cushman was a Senior Fulbright Scholar at Munich Technical University working in the laboratory of Professor Adelbert Bacher. His sabbatical work dealt with the design and synthesis of probes to elucidate key aspects of the biosynthesis of riboflavin (vitamin B2). [3] Currently he holds the rank of Distinguished Professor Emeritus of Medicinal Chemistry at Purdue University. [4] He has mentored 40 graduate students, 59 postdoctoral researchers, and 5 visiting scholars. He has published 348 papers and holds 41 patents. His work has ~17,000 citations with an h-index of 69. His most cited papers had 471, 403, and 299 citations as of August 2021. [4] He has made seminal contributions to the fields of synthetic and medicinal chemistry including the development of new synthetic methodologies, the synthesis of natural products, and the preparation of antivirals, antibacterials, and anticancer agents, and mechanism probes to understand the function of over thirty macromolecular targets. [4] One of his main scientific contributions is the development of the indenoisoquinolines, molecules that inhibit the action of toposiomerase I (Top1) and stabilize the G-quadruplex in the Myc promoter. [5] Three indenoisoquinolines designed and synthesized by his research group at Purdue University [indotecan (LMP 400), indimitecan (LMP 776), and LMP 744] demonstrated potent anticancer activity in vivo and have completed phase I clinical trials at the National Institutes of Health. [6]

Contents

Personal life

Mark Cushman was born on August 20, 1945, in the city of Fresno, California.  A main influence during his formative years was his maternal grandfather, Stanley Borleske, who taught engineering and mathematics at Fresno State College. Mr. Borleske also worked as head football, basketball, and baseball coach at Fresno State College. Besides instilling his love for football, his grandfather influenced traits such as coaching/mentoring, hard-work, a special attention to detail, planning, ethics, and love for learning. These attributes have been the hallmarks of Professor Cushman's character. [7]  

The Castagnoli-Cushman reaction

Synthesis of an indenoisoquinoline using the Castagnoli-Cushman reaction Indeno-1.png
Synthesis of an indenoisoquinoline using the Castagnoli-Cushman reaction

In the 1970's, while working in the group of Neal Castagnoli, Jr., Ph.D., he reported and studied in detail the condensation of cyclic anhydrides with imines [8] (work that was based on a previous report by Castagnoli [9] ). This reaction is currently known as the Castagnoli-Cushman reaction. One of its first applications was for the preparation of nitrogen analogues of tetrahydrocannabinol, a pharmacologically active natural product isolated from Cannabis sativa. [10] This versatile transformation has been used to generate polysubstituted lactam carboxylic acids and to prepare benzophenanthridine and protoberberine alkaloids, and hundreds of indenoisoquinolines. [11] [12] [13] A general scheme of the Cushman-Castagnoli reaction, applied to the synthesis of a model indenoisoquinoline, is shown to the right. Later, the conditions were optimized and include the formation of an acyl chloride followed by condensation using AlCl3. [14] [15]

Development of the indenoisoquinolines

An alternative synthetic method for the preparation of an indenoisoquinoline Indenoiso2.png
An alternative synthetic method for the preparation of an indenoisoquinoline

Dr. Cushman is the world leader in the design and synthesis of the indenoisoquinolines. [16] These drugs, which were discovered serendipitously during a synthesis of the antileukemic agent nitidine chloride, can eradicate cancer cells. The seminal paper describing the synthesis of the molecules, using the Castagnoli-Cushman Reaction, was published in The Journal of Organic Chemistry. [17]   Alternatively, the indenoisoquinolines can be prepared by reacting a benz[d]indeno[1,2-b]pyran-5,11-dione (I) with an amine (II).

Initially, it was discovered the indenoisoquinolines inhibited the action of the topoisomerase I enzyme. [18] [19] Later, it was found these molecules can also affect other targets including the retinoid X receptor (RXR), [20] poly [ADP-ribose] polymerase 1 (PARP-1), [21] topoisomerase II, [22] estrogen receptor, [23] vascular endothelial growth factor-2 (VEGFR-2), [23] hypoxia-inducible factor 1-alpha (HIF-1a), [24] tyrosyl DNA phosphodiesterases (TDP) 1 and 2, and G-quadruplexes. [5]

In addition, the Cushman group and collaborators have reported that indenoisoquinolines could potentially treat other diseases including visceral Leishmaniasis, African trypanosomiasis (sleeping sickness), and Angelman syndrome.

Total synthesis

Selected natural products synthesized by Mark Cushman and co-workers Total Synthesis Cushman.png
Selected natural products synthesized by Mark Cushman and co-workers

Another main contribution of Mark Cushman and his group deals with the synthesis of various natural products and pharmacologically active synthetic substances. Some of the compounds his group prepared include: the antileukemic agent nitidine chloride (III); [25] corydaline, [26] which possesses antinociceptive and antiallergic activities among others; thalictricavine, [27] an inhibitor of human acetylcholinesterase and butyrylcholinesteras; [28] berlambine; [27] (±)-canadine; (+)-thalictrifoline; [29] cosalane (IV), [30] a molecule that inhibits HIV by acting on various targets; [31] (±) chelidonine, [32] a non-specific cholinesterase inhibitor; ammosamide B (V), [33] a cytotoxic natural product that targets myosin; [34] lavendustin A (VI), [35] a tyrosine kinase inhibitor; [36] and (+)- and (–)-corynoline. [37] [38]

Awards and honors

Professor Cushman has received various awards including:

Others

Dr. Cushman served on the Editorial Advisory Board of The Journal of Organic Chemistry (1999–2004). He also served on the Editorial Advisory Board (2005–2010) and as Associate Editor (2012–2020) of The Journal of Medicinal Chemistry. He is a member of the Board of Directors of Gibson Oncology.

Related Research Articles

<span class="mw-page-title-main">Benzyl group</span> Chemical group (–CH₂–C₆H₅)

In organic chemistry, benzyl is the substituent or molecular fragment possessing the structure R−CH2−C6H5. Benzyl features a benzene ring attached to a methylene group group.

<span class="mw-page-title-main">Wacker process</span>

The Wacker process or the Hoechst-Wacker process refers to the oxidation of ethylene to acetaldehyde in the presence of palladium(II) chloride and copper(II) chloride as the catalyst. This chemical reaction was one of the first homogeneous catalysis with organopalladium chemistry applied on an industrial scale.

The Negishi coupling is a widely employed transition metal catalyzed cross-coupling reaction. The reaction couples organic halides or triflates with organozinc compounds, forming carbon-carbon bonds (C-C) in the process. A palladium (0) species is generally utilized as the metal catalyst, though nickel is sometimes used. A variety of nickel catalysts in either Ni0 or NiII oxidation state can be employed in Negishi cross couplings such as Ni(PPh3)4, Ni(acac)2, Ni(COD)2 etc.

Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single- and double stranded DNA breaks they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

<i>sec</i>-Butyllithium Chemical compound

sec-Butyllithium is an organometallic compound with the formula CH3CHLiCH2CH3, abbreviated sec-BuLi or s-BuLi. This chiral organolithium reagent is used as a source of sec-butyl carbanion in organic synthesis.

<span class="mw-page-title-main">Achmatowicz reaction</span> Organic synthesis

The Achmatowicz reaction, also known as the Achmatowicz rearrangement, is an organic synthesis in which a furan is converted to a dihydropyran. In the original publication by the Polish Chemist Osman Achmatowicz Jr. in 1971 furfuryl alcohol is reacted with bromine in methanol to 2,5-dimethoxy-2,5-dihydrofuran which rearranges to the dihydropyran with dilute sulfuric acid. Additional reaction steps, alcohol protection with methyl orthoformate and boron trifluoride) and then ketone reduction with sodium borohydride produce an intermediate from which many monosaccharides can be synthesised.

In organic chemistry, diazirines are a class of organic molecules consisting of a carbon bound to two nitrogen atoms, which are double-bonded to each other, forming a cyclopropene-like ring, 3H-diazirene. They are isomeric with diazocarbon groups, and like them can serve as precursors for carbenes by loss of a molecule of dinitrogen. For example, irradiation of diazirines with ultraviolet light leads to carbene insertion into various C−H, N−H, and O−H bonds. Hence, diazirines have grown in popularity as small, photo-reactive, crosslinking reagents. They are often used in photoaffinity labeling studies to observe a variety of interactions, including ligand-receptor, ligand-enzyme, protein-protein, and protein-nucleic acid interactions.

<span class="mw-page-title-main">Anthony Barrett</span> British chemist

Anthony Gerard Martin Barrett FRS, FMedSci is a British chemist, and Sir Derek Barton Professor of Synthesis, Glaxo Professor of Organic Chemistry at Imperial College London. He is Director of the Wolfson Centre for Organic Chemistry in Medical Science. He was elected a fellow of the Royal Society in 1999 and Academy of Medical Sciences in 2003. He obtained a BSc as well as PhD from Imperial College London in 1973 and 1975 respectively.

<span class="mw-page-title-main">Lavendamycin</span> Chemical compound

Lavendamycin is a naturally occurring chemical compound discovered in fermentation broth of the soil bacterium Streptomyces lavendulae. Lavendamycin has antibiotic properties and anti-proliferative effects against several cancer cell lines. The use of lavendamycin as a cytotoxic agent in cancer therapy failed due to poor water solubility and non-specific cytotoxicity. The study of lavendamycin-based analogs designed to overcome these liabilities has been an area of research.

The Davis–Beirut reaction is N,N-bond forming heterocyclization that creates numerous types of 2H-indazoles and indazolones in both acidic and basic conditions The Davis–Beirut reaction is named after Mark Kurth and Makhluf Haddadin's respective universities; University of California, Davis and American University of Beirut, and is appealing because it uses inexpensive starting materials and does not require toxic metals.

David Markham Lemal is the Albert W. Smith Professor of Chemistry Emeritus and Research Professor of Chemistry at Dartmouth College. He received an A.B. degree (summa) from Amherst College in 1955 and a Ph.D. in chemistry from Harvard University in 1959. At Harvard he worked with R. B. Woodward on deoxy sugars and a synthesis of the alkaloid yohimbine.

Peter Wipf is the distinguished university professor of chemistry at the University of Pittsburgh. His research interests focus on the total synthesis of natural products, the discovery of new transformations of strained molecules, and the development of new pharmaceuticals. He is a Fellow of the Royal Society of Chemistry (RSC), the American Association for the Advancement of Science (AAAS), and the American Chemical Society (ACS).

<span class="mw-page-title-main">MoOPH</span> Chemical compound

MoOPH, also known as oxodiperoxymolybdenum(pyridine)-(hexamethylphosphoric triamide), is a reagent used in organic synthesis. It contains a molybdenum(VI) center with multiple oxygen ligands, coordinated with pyridine and HMPA ligands. It is an electrophilic source of oxygen that reacts with enolates and related structures, and thus can be used for alpha-hydroxylation of carbonyl-containing compounds. Other reagents used for alpha-hydroxylation via enol or enolate structures include Davis oxaziridine, oxygen, and various peroxyacids. This reagent was first utilized by Edwin Vedejs as an efficient alpha-hydroxylating agent in 1974 and an effective preparative procedure was later published in 1978.

In organic chemistry, the Fujiwara–Moritani reaction is a type of cross coupling reaction where an aromatic C-H bond is directly coupled to an olefinic C-H bond, generating a new C-C bond. This reaction is performed in the presence of a transition metal, typically palladium. The reaction was discovered by Yuzo Fujiwara and Ichiro Moritani in 1967. An external oxidant is required to this reaction to be run catalytically. Thus, this reaction can be classified as a C-H activation reaction, an oxidative Heck reaction, and a C-H olefination. Surprisingly, the Fujiwara–Moritani reaction was discovered before the Heck reaction.

The Riley oxidation is a selenium dioxide-mediated oxidation of methylene groups adjacent to carbonyls. It was first reported by Riley and co-workers in 1932. In the decade that ensued, selenium-mediated oxidation rapidly expanded in use, and in 1939, Guillemonat and co-workers disclosed the selenium dioxide-mediated oxidation of olefins at the allylic position. Today, selenium-dioxide-mediated oxidation of methylene groups to alpha ketones and at the allylic position of olefins is known as the Riley Oxidation.

Clark Landis is an American chemist, whose research focuses on organic and inorganic chemistry. He is currently a Professor of Chemistry at the University of Wisconsin–Madison. He was awarded the ACS Award in Organometallic Chemistry in 2010, and is a fellow of the American Chemical Society and the American Association for the Advancement of Science.

<span class="mw-page-title-main">Mizoroki-Heck vs. Reductive Heck</span>

The Mizoroki−Heck coupling of aryl halides and alkenes to form C(sp2)–C(sp2) bonds has become a staple transformation in organic synthesis, owing to its broad functional group compatibility and varied scope. In stark contrast, the palladium-catalyzed reductive Heck reaction has received considerably less attention, despite the fact that early reports of this reaction date back almost half a century. From the perspective of retrosynthetic logic, this transformation is highly enabling because it can forge alkyl–aryl linkages from widely available alkenes, rather than from the less accessible and/or more expensive alkyl halide or organometallic C(sp3) synthons that are needed in a classical aryl/alkyl cross-coupling.

The Stahl oxidation is a copper-catalyzed aerobic oxidation of primary and secondary alcohols to aldehydes and ketones. Known for its high selectivity and mild reaction conditions, the Stahl oxidation offers several advantages over classical alcohol oxidations.

T.V. (Babu) RajanBabu is an organic chemist who holds the position of Distinguished Professor of Chemistry in the College of Arts and Sciences at the Ohio State University. His laboratory traditionally focuses on developing transition metal-catalyzed reactions. RajanBabu is known for helping develop the Nugent-RajanBabu reagent, a chemical reagent used in synthetic organic chemistry as a single electron reductant.

Kathlyn Ann Parker is a chemist known for her work on synthesis of compounds, especially organic compounds with biological roles. She is an elected fellow of the American Chemical Society and a recipient of the Garvan–Olin Medal in chemistry.

References

  1. ↑ Buchi, George; Cushman, Mark; Wuest, Hans (1974-08-01). "Conversion of allylic alcohols to homologous amides by N,N-dimethylformamide acetals". Journal of the American Chemical Society. 96 (17): 5563–5565. doi:10.1021/ja00824a041. ISSN   0002-7863.
  2. ↑ Anderegg, Robert J.; Biemann, Klaus; Buechi, George; Cushman, Mark (1976-05-01). "Malformin C, a new metabolite of Aspergillus niger". Journal of the American Chemical Society. 98 (11): 3365–3370. doi:10.1021/ja00427a051. ISSN   0002-7863. PMID   1262650.
  3. ↑ Cushman, Mark; Patrick, Donald A.; Bacher, Adelbert; Scheuring, Johannes (1991-07-01). "Synthesis of epimeric 6,7-bis(trifluoromethyl)-8-ribityllumazine hydrates. Stereoselective interaction with the light riboflavin synthase of Bacillus subtilis". The Journal of Organic Chemistry. 56 (15): 4603–4608. doi:10.1021/jo00015a009. ISSN   0022-3263.
  4. 1 2 3 "Mark S. Cushman" . Retrieved August 24, 2021.{{cite web}}: CS1 maint: url-status (link)
  5. 1 2 Wang, Kai-Bo; Elsayed, Mohamed S. A.; Wu, Guanhui; Deng, Nanjie; Cushman, Mark; Yang, Danzhou (2019-07-17). "Indenoisoquinoline Topoisomerase Inhibitors Strongly Bind and Stabilize the MYC Promoter G-Quadruplex and Downregulate MYC". Journal of the American Chemical Society. 141 (28): 11059–11070. doi:10.1021/jacs.9b02679. ISSN   0002-7863. PMC   7307421 . PMID   31283877.
  6. ↑ Pommier, Yves; Cushman, Mark; Doroshow, James H. (2018-12-18). "Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins". Oncotarget. 9 (99): 37286–37288. doi:10.18632/oncotarget.26466. ISSN   1949-2553. PMC   6324668 . PMID   30647868.
  7. ↑ Conda-Sheridan, Martin (2019). "Editorial page, special issue honoring Professor Mark Cushman". Medicinal Research Reviews. 39 (4): 1233–1234. doi: 10.1002/med.21583 . ISSN   1098-1128. PMID   31194276.
  8. ↑ Castagnoli, Neal; Cushman, Mark (November 1971). "Condensation of succinic anhydrides with Schiff bases. Scope and mechanism". The Journal of Organic Chemistry. 36 (22): 3404–3406. doi:10.1021/jo00821a029. ISSN   0022-3263. PMID   5132298.
  9. ↑ Castagnoli, Neal (1969-10-01). "Condensation of succinic anhydride with N-benzylidene-N-methylamine. Stereoselective synthesis of trans- and cis-1-methyl-4-carboxy-5-phenyl-2-pyrrolidinone". The Journal of Organic Chemistry. 34 (10): 3187–3189. doi:10.1021/jo01262a081. ISSN   0022-3263. PMID   5811404.
  10. ↑ Cushman, M.; Castagnoli, N. (1974-05-31). "Synthesis of pharmacologically active nitrogen analogs of the tetrahydrocannabinols". The Journal of Organic Chemistry. 39 (11): 1546–1550. doi:10.1021/jo00924a021. ISSN   0022-3263. PMID   4833507.
  11. ↑ Mikheyev, Alexander; Kantin, Grigory; Krasavin, Mikhail (May 2018). "Aldazines in the Castagnoli–Cushman Reaction". Synthesis. 50 (10): 2076–2086. doi:10.1055/s-0037-1609375. ISSN   0039-7881. S2CID   103885937.
  12. ↑ Howard, Sara Y.; Di Maso, Michael J.; Shimabukuro, Kristin; Burlow, Noah P.; Tan, Darlene Q.; Fettinger, James C.; Malig, Thomas C.; Hein, Jason E.; Shaw, Jared T. (2021-08-05). "Mechanistic Investigation of Castagnoli–Cushman Multicomponent Reactions Leading to a Three-Component Synthesis of Dihydroisoquinolones". The Journal of Organic Chemistry. 86 (17): 11599–11607. doi:10.1021/acs.joc.1c01163. ISSN   0022-3263. PMID   34351161. S2CID   236927425.
  13. ↑ Firsov, Andrei; Chupakhin, Evgeny; Dar’in, Dmitry; Bakulina, Olga; Krasavin, Mikhail (2019-03-15). "Three-Component Castagnoli–Cushman Reaction of 3-Arylglutaconic Acids with Aromatic Aldehydes and Amines Delivers Rare 4,6-Diaryl-1,6-dihydropyridin-2(3H)-ones". Organic Letters. 21 (6): 1637–1640. doi:10.1021/acs.orglett.9b00171. ISSN   1523-7060. PMID   30794425. S2CID   73506357.
  14. ↑ Morrell, Andrew; Antony, Smitha; Kohlhagen, Glenda; Pommier, Yves; Cushman, Mark (2004-07-16). "Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors". Bioorganic & Medicinal Chemistry Letters. 14 (14): 3659–3663. doi:10.1016/j.bmcl.2004.05.022. ISSN   0960-894X. PMID   15203138.
  15. ↑ Conda-Sheridan, Martin; Reddy, P. V. Narasimha; Morrell, Andrew; Cobb, Brooklyn T.; Marchand, Christophe; Agama, Keli; Chergui, Adel; Renaud, Amélie; Stephen, Andrew G.; Bindu, Lakshman K.; Pommier, Yves (2012-12-21). "Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1)". Journal of Medicinal Chemistry. 56 (1): 182–200. doi:10.1021/jm3014458. ISSN   0022-2623. PMC   3542538 . PMID   23259865.
  16. ↑ Cushman, Mark (2021-12-08). "Design and Synthesis of Indenoisoquinolines Targeting Topoisomerase I and Other Biological Macromolecules for Cancer Chemotherapy". Journal of Medicinal Chemistry. 64 (24): 17572–17600. doi:10.1021/acs.jmedchem.1c01491. ISSN   0022-2623. PMID   34879200. S2CID   245065452.
  17. ↑ Cushman, Mark; Cheng, Leung (1978-09-01). "Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system". The Journal of Organic Chemistry. 43 (19): 3781–3783. doi:10.1021/jo00413a036. ISSN   0022-3263.
  18. ↑ Kohlhagen, Glenda; Paull, Kenneth D.; Cushman, Mark; Nagafuji, Pamela; Pommier, Yves (1998-07-01). "Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison". Molecular Pharmacology. 54 (1): 50–58. doi:10.1124/mol.54.1.50. ISSN   0026-895X. PMID   9658189.
  19. ↑ Antony, Smitha; Jayaraman, Muthusamy; Laco, Gary; Kohlhagen, Glenda; Kohn, Kurt W.; Cushman, Mark; Pommier, Yves (2003-11-01). "Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I". Cancer Research. 63 (21): 7428–7435. ISSN   0008-5472. PMID   14612542.
  20. ↑ Park, Eun-Jung; Kondratyuk, Tamara P.; Morrell, Andrew; Kiselev, Evgeny; Conda-Sheridan, Martin; Cushman, Mark; Ahn, Soyoun; Choi, Yongsoo; White, Jerry J.; van Breemen, Richard B.; Pezzuto, John M. (April 2011). "Induction of retinoid X receptor activity and consequent up-regulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells". Cancer Prevention Research (Philadelphia, Pa.). 4 (4): 592–607. doi:10.1158/1940-6207.CAPR-10-0004. ISSN   1940-6207. PMC   5554444 . PMID   21464033.
  21. ↑ Jagtap, Prakash G.; Baloglu, Erkan; Southan, Garry J.; Mabley, Jon G.; Li, Hongshan; Zhou, Jing; van Duzer, John; Salzman, Andrew L.; Szabó, Csaba (2005-08-01). "Discovery of Potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the Modification of Indeno[1,2-c]isoquinolinone". Journal of Medicinal Chemistry. 48 (16): 5100–5103. doi:10.1021/jm0502891. ISSN   0022-2623. PMID   16078828.
  22. ↑ Marzi, Laetitia; Sun, Yilun; Huang, Shar-yin N.; James, Amy; Difilippantonio, Simone; Pommier, Yves (2020-08-01). "The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2". Molecular Cancer Therapeutics. 19 (8): 1589–1597. doi:10.1158/1535-7163.MCT-19-1064. ISSN   1535-7163. PMC   7415565 . PMID   32430490.
  23. 1 2 Tang, Zhichao; Wu, Chengzhe; Wang, Tianlin; Lao, Kejing; Wang, Yejun; Liu, Linyi; Muyaba, Moses; Xu, Pei; He, Conghui; Luo, Guoshun; Qian, Zhouyang (2016-08-08). "Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents". European Journal of Medicinal Chemistry. 118: 328–339. doi:10.1016/j.ejmech.2016.04.029. ISSN   0223-5234. PMID   27176944.
  24. ↑ Xu, Xiaoli; Liu, Fang; Zhang, Shengmiao; Jia, Jianmin; Li, Zhiyu; Guo, Xiaoke; Yang, Yong; Sun, Haopeng; You, Qidong (2013-10-01). "Indenoisoquinoline derivatives as topoisomerase I inhibitors that suppress angiogenesis by affecting the HIF signaling pathway". Biomedicine & Pharmacotherapy. 67 (8): 715–722. doi:10.1016/j.biopha.2013.06.004. ISSN   0753-3322. PMID   23932721.
  25. ↑ Cushman, Mark; Cheng, Leung (January 1978). "Total synthesis of nitidine chloride". The Journal of Organic Chemistry. 43 (2): 286–288. doi:10.1021/jo00396a024. ISSN   0022-3263.
  26. ↑ Cushman, Mark; Dekow, Frederick W. (1978-01-01). "A total synthesis of corydaline". Tetrahedron. 34 (10): 1435–1439. doi:10.1016/0040-4020(78)80162-8. ISSN   0040-4020.
  27. 1 2 Cushman, Mark; Dekow, Frederick W. (1979-02-01). "Synthesis of (.+-.)-thalictricavine, berlambine, and (.+-.)-canadine from a common intermediate". The Journal of Organic Chemistry. 44 (3): 407–409. doi:10.1021/jo01317a020. ISSN   0022-3263.
  28. ↑ Chlebek, Jakub; Korábečný, Jan; Doležal, Rafael; Štěpánková, Šárka; Pérez, Daniel I.; Hošťálková, Anna; Opletal, Lubomír; Cahlíková, Lucie; Macáková, Kateřina; Kučera, Tomáš; Hrabinová, Martina (January 2019). "In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier". Molecules. 24 (7): 1340. doi: 10.3390/molecules24071340 . PMC   6480038 . PMID   30959739.
  29. ↑ Iwasa, Kinuko; Gupta, Yash Pal; Cushman, Mark (1981-01-01). "The absolute configurations of (+)-thalictrifoline and (+)-corydalic acid methyl ester. Total synthesis of (+)-thalictrifoline". Tetrahedron Letters. 22 (25): 2333–2336. doi:10.1016/S0040-4039(01)82899-9. ISSN   0040-4039.
  30. ↑ Cushman, Mark; Golebiewski, W. Marek; McMahon, James B.; Buckheit, Robert W.; Clanton, David J.; Weislow, Owen; Haugwitz, Rudiger D.; Bader, John P.; Graham, Lisa; Rice, William G. (September 1994). "Design, Synthesis, and Biological Evaluation of Cosalane, a Novel Anti-HIV Agent Which Inhibits Multiple Features of Virus Reproduction". Journal of Medicinal Chemistry. 37 (19): 3040–3050. doi:10.1021/jm00045a008. ISSN   0022-2623. PMID   7932526.
  31. ↑ Zhan, Peng; Li, Zhenyu; Liu, Xinyong (September 2010). "Cosalane and its analogues: a unique class of anti-HIV agents". Mini Reviews in Medicinal Chemistry. 10 (10): 966–976. doi:10.2174/138955710792007222. ISSN   1875-5607. PMID   20540707.
  32. ↑ Cushman, Mark; Choong, Tung-Chung; Valko, Joseph T.; Koleck, Mary P. (1980-12-01). "Total synthesis of (.+-.)-chelidonine". The Journal of Organic Chemistry. 45 (25): 5067–5073. doi:10.1021/jo01313a011. ISSN   0022-3263.
  33. ↑ Reddy, P. V. Narasimha; Banerjee, Biplab; Cushman, Mark (2010-07-02). "Efficient Total Synthesis of Ammosamide B". Organic Letters. 12 (13): 3112–3114. doi:10.1021/ol101215x. ISSN   1523-7060. PMC   2894265 . PMID   20515072.
  34. ↑ Hughes, Chambers C.; MacMillan, John B.; Gaudêncio, Susana P.; Fenical, William; La Clair, James J. (2009). "Ammosamides A and B Target Myosin". Angewandte Chemie International Edition. 48 (4): 728–732. doi:10.1002/anie.200804107. ISSN   1521-3773. PMC   2820877 . PMID   19097126.
  35. ↑ Devraj, Rajesh; Cushman, Mark (1996-01-01). "A Versatile Solid Phase Synthesis of Lavendustin A and Certain Biologically Active Analogs". The Journal of Organic Chemistry. 61 (26): 9368–9373. doi:10.1021/jo961719l. ISSN   0022-3263.
  36. ↑ Onoda, Toshihiko; Iinuma, Hironobu; Sasaki, Yumi; Hamada, Masa; Isshiki, Kunio; Naganawa, Hiroshi; Takeuchi, Tomio; Tatsuta, Kuniaki; Umezawa, Kazuo (1989-11-01). "Isolation of a Novel Tyrosine Kinase Inhibitor, Lavendustin A, from Streptomyces griseolavendus". Journal of Natural Products. 52 (6): 1252–1257. doi:10.1021/np50066a009. ISSN   0163-3864. PMID   2614420.
  37. ↑ Cushman, Mark; Abbaspour, Aziz; Gupta, Yash Pal (1983-05-01). "Total synthesis of (.+-.)-14-epicorynoline, (.+-.)-corynoline, and (.+-.)-6-oxocorynoline". Journal of the American Chemical Society. 105 (9): 2873–2879. doi:10.1021/ja00347a057. ISSN   0002-7863.
  38. ↑ Cushman, Mark; Abbaspour, Aziz; Gupta, Yash Pal (1990-07-01). "Total synthesis of (.+-.)-14-epicorynoline, (.+-.)-corynoline, and (.+-.)-6-oxocorynoline [Erratum to document cited in CA98(21):179711f]". Journal of the American Chemical Society. 112 (15): 5898. doi:10.1021/ja00171a050. ISSN   0002-7863.
  39. ↑ "Purdue University Chapter of Sigma Xi Research Award in Science and Engineering".{{cite web}}: CS1 maint: url-status (link)
  40. ↑ "Philip S. Portoghese Joint Lectureship".{{cite web}}: CS1 maint: url-status (link)
  41. ↑ "Ole Gisvold Lectureship Award in Medicinal Chemistry". 8 September 2015.{{cite web}}: CS1 maint: url-status (link)
  42. ↑ "National Academy of Inventors Fellow".{{cite web}}: CS1 maint: url-status (link)
  43. ↑ "Highly Prolific Author by the Journal of Medicinal Chemistry".{{cite web}}: CS1 maint: url-status (link)
  44. ↑ "Purdue Innovators Hall of Fame".{{cite web}}: CS1 maint: url-status (link)
  45. ↑ "University of California San Francisco 150th Anniversary Alumni Excellence Award".{{cite web}}: CS1 maint: url-status (link)
  46. ↑ "Webster-Sibilsky Lectureship".{{cite web}}: CS1 maint: url-status (link)
  47. ↑ "American Association for the Advancement of Science Fellowship Award" (PDF).{{cite web}}: CS1 maint: url-status (link)
  48. ↑ "Chaney Scholar Award for Exceptional Research".{{cite web}}: CS1 maint: url-status (link)
  49. ↑ "Purdue Cancer Research Award".{{cite web}}: CS1 maint: url-status (link)
  50. 1 2 "Purdue trustees ratify appointments, honor administrators and athletes, confirm retirement plan change, approve coal purchase". www.purdue.edu. Retrieved 2021-08-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.